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ABSTRACT 
Objective 
To establish the level of opioid prescribing for patients with chronic musculoskeletal 
pain in a sample of patients from primary care and to estimate prescription costs. 
Design 
Secondary data analyses from a two-arm pragmatic randomised controlled trial 
(COPERS) testing the effectiveness of group self-management course and usual 
care against relaxation and usual care for patients with chronic musculoskeletal pain. 
(ISRCTN 24426731) 
Setting 
25 general practices and 2 community musculoskeletal services in the UK (London 
and Midlands) 
Participants 
703 chronic pain participants; 81% white, 67% female, enrolled in the COPERS trial. 
Main outcome measures 
Anonymised prescribing data over 12 months extracted from GP electronic records.  
Results 
Of the 703 trial participants with chronic musculoskeletal pain, 413 (59%) patients 
were prescribed opioids. Among those prescribed an opioid, the number of opioid 
prescriptions varied from 1 to 52 per year. A total of 3,319 opioid prescriptions were 
issued over the study period, of which 53% (1,768/3,319) were for strong opioids 
(tramadol, buprenorphine, morphine, oxycodone, fentanyl and tapentadol). The 
mean number of opioid prescriptions per patient prescribed any opioid was 8.0 
(SD=7.9). A third of patients on opioids were prescribed more than one substance; 
the most frequent combinations were: codeine plus tramadol and codeine plus 
morphine. The cost of opioid prescriptions per patient per year varied from £3 to 
£4,844. The average annual prescription cost was £24 (SD=29) for patients 
prescribed weak opioids and £174 (SD=421) for patients prescribed strong opioids. 
Approximately 40% of patients received >3 prescriptions of strong opioids per year, 
with an annual cost of £236 per person.  
Conclusions 
Long-term prescribing of opioids for chronic musculoskeletal pain is common in 
primary care. More than a quarter of patients receiving strong opioids may have 
been over-prescribed according to national guidelines.  
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Trial registration number: ISRCTN 24426731 COPERS trial  
 
Strengths and limitations of this study 
Strengths of this study are: 
 This study presents analyses of opioids prescribing data over 12 months 
extracted from GP electronic records;  
 This study estimates the cost of over-prescribing opioids in primary care. 
Limitations of this study are: 
 This study does not look at longitudinal changes in prescribing opioids to 
patients with chronic musculoskeletal pain. 
 This study does not attempt to relate opioid prescriptions with treatment 
effectiveness. 
 
Introduction 
“Few things a doctor does are more important than relieving pain … pain is soul 
destroying”.1 These words from Marcia Angell, former editor-in-chief of the New 
England Medical Journal, succinctly illustrate the therapeutic need for pain relief. 
However, prescribers have to balance both benefits and harm to patients from 
pharmacological treatment. Untreated pain can cause both physical and mental 
distress. One in five people suffer from chronic pain, the most common sources 
being back pain (24%) or osteoarthritis (35%).2 3 Findings from the Global Burden of 
Disease study highlight musculoskeletal conditions as the largest cause of disability 
in the UK.4 Pain is the main symptom of many musculoskeletal conditions and it is 
closely associated with depression, anxiety, fatigue and sleep deprivation. The WHO 
recognizes chronic musculoskeletal pain as a global priority and aims to better alert 
nations to the health and economic costs brought about by musculoskeletal 
conditions.5 
Opioids are a popular form of analgesia. Up to 90% of individuals presenting to pain 
centres receive opioids.6 There is a lack of evidence supporting the efficacy of 
opioids for chronic non-malignant pain management. Several studies have 
demonstrated that opioids achieve negligible improvements in pain, function and 
quality of life.7-10 In addition, as prescribed doses of opioids increase so does the risk 
of adverse effects such as depression, anxiety, headaches, insomnia, inadvertent 
4 
 
overdose and death.11 According to a UK Office of National Statistics report,12 
accidental drug overdose is rising, with the highest number recorded since 
comparable records began in 1993. Of the 3,346 drug poisoning deaths registered, 
53% involved an opiate drug.12 The UK guidelines on chronic pain management for 
people with low back pain and osteoarthritis 13-16 recommend weak opioids as a 
second-line treatment when the first-line medication (NSAIDS, paracetamol or 
coxibs) is ineffective or not tolerated. Strong opioids are to be only prescribed for 
unremitting cases and even then for short term use only, stepping patients down to 
weaker opioids as appropriate, or removing altogether if not effective.15 
In past years, there has been a range of publications from both media and the 
medical profession suggesting that prescribed opioid doses are too high and are 
prescribed for too long, actually endangering patients.17-19 An editorial in The BMJ 
entitled: “Opioids in the UK: What is the problem?”20 concisely summarised concerns 
from the growing qualitative literature on the over-prescription of opioids for chronic 
non-malignant pain. There is a growing apprehension that the rise in drug-related 
deaths parallels a rise in opioid prescriptions.9 21-23 However, this is an argument 
based upon evidence from the USA, where rising numbers of deaths have involved 
prescription drug overdoses.24-26 There are few reliable data on opioid prescriptions 
in the UK to infer whether over-prescription is an issue. 
In this study our aim was to explore opioid prescribing in a sample of chronic 
musculoskeletal pain patients in primary care and to estimate the associated costs. 
We conducted secondary analyses of prescription data from the COPERS trial: a 
randomised, multi-centre, pragmatic trial of a non-pharmacological group 
intervention for people with chronic musculoskeletal pain conducted across 27 
general practices and musculoskeletal services across the UK.27-29 We undertook a 
secondary analysis looking at the entire cohort of patients to characterise patterns of 
opioid prescription and to estimate the opioid prescription cost. We also looked at the 
regional differences in opioid prescribing between two UK geographical areas - 
London and the Midlands. 
 
Methods 
Data sources and study characteristics 
We used an anonymised database from the COPERS trial that contained the 
prescription data for the 703 participants. Study design, setting and participants' 
characteristics are described in detail elsewhere.28 29 Briefly, COPERS was a multi-
centre, pragmatic, randomised controlled effectiveness and cost-effectiveness trial 
conducted in the UK from 2011 to 2012. Seven hundred and three adults with 
musculoskeletal pain were randomised using a ratio 1.33:1 to intervention (n=403) or 
control (n=300). In the intervention group, the participants had usual care and were 
offered a group self-management intervention using cognitive behavioural 
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approaches for the non-pharmacological management of chronic pain (the COPERS 
course). The primary outcome was pain-related disability at 12 months (Chronic Pain 
Grade disability subscale). There were a wide range of secondary outcome 
measures which included the Hospital Anxiety and Depression Scale (HADS), health 
care resource use, and EQ-5D-3L. Health care resource use data included 
information on the number of contacts with primary and secondary health care 
services, and prescribing data which were collected from participants’ GP electronic 
records at 12 months. There were no serious adverse events reported in the trial. 
The study did not find any significant differences in prescribing opioids between the 
intervention and control groups.29 We therefore conducted cohort analyses using 
data for both groups to characterise opioid prescribing for people with chronic 
musculoskeletal pain. 
 
Participants 
The characteristics of study participants and recruitment procedures are described 
elsewhere.27 Briefly, participants were adults (≥18 years) with musculoskeletal pain 
of at least three months duration. Causes of pain included, but were not restricted to: 
osteoarthritis, back pain, chronic widespread pain, and fibromyalgia. Participants 
were recruited in the UK (London and the Midlands) from primary care, community 
musculoskeletal pain services, and secondary care pain services. Exclusion criteria 
were: inability to give informed consent, not fluent in English, chronic pain arising 
from active malignant disease or inflammatory arthritis, terminal illness, or serious 
uncontrolled mental health or substance abuse preventing individuals from 
participating in the group sessions. The demography of the study participants was: 
67% female, mean age 60 years (52 years in London and 67 in Midlands) and 81% 
white British. 
 
Prescription analysis 
We extracted and anonymised prescribing data over 12 months from participants’ 
GP electronic records. The dataset included information on: formulation, 
dose/strength, and the number of prescription items for each participant. A 
“prescription” refers to a single medicine prescribed by a doctor on a prescription 
form. The dataset contained 40,649 prescriptions in total; these included other items 
as well as opioids. Opioids were identified in the dataset by their generic (non-
proprietary) names using the BNF classification system.30 Searches were conducted 
for strong opioids: buprenorphine, diamorphine, dipipanone, fentanyl, morphine, 
oxycodone, papaveretum, pentazocine, pethidine, tapentadol and tramadol, and 
weak opioids: codeine, dihydrocodeine and meptazinol. We also searched for 
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combination formulations which contained weak opioids: co-codamol (codeine 
phosphate/paracetamol) and co-dydramol (dihydrocodeine/paracetamol). The 
searches were conducted using wildcards and the VLOOKUP option in Microsoft 
Excel. The two-way multivariate analysis of variance (MANOVA) was conducted 
using IBM SPSS Statistics. The cost of opioid prescriptions was calculated using the 
Prescription Cost Analysis (PCA) database31 using a net ingredient cost per item 
(cost without discount and dispensing fees per single item prescribed on a 
prescription form). The list of costs used in the study is shown in Appendix 1.  We did 
not compare oral morphine equivalent doses due to lack of consistency in the 
conversion ratios taken from different sources.32-34 
Results 
For the 703 study participants, 413 (59%) were prescribed opioids. In total, 3,319 
opioid prescriptions were issued over the 12-month period, of which 53% 
(1,768/3,319) were for strong opioids (tramadol, buprenorphine, morphine, 
oxycodone, fentanyl and tapentadol). The number of opioid prescriptions varied from 
1 to 52 per person per year. The average number of opioid prescriptions per patient 
was 8.0 (SD=7.9). Table 1 shows the annual numbers of opioid prescriptions and 
their costs. The cost per prescription varied from £4 to £63 with oxycodone being the 
most costly opioid prescription. The overall cost of all prescribed opioids during the 
12 month study period was £44,491 (on average £63.29 per participant). 
 
Table 1. Annual numbers of prescriptions and their costs (N=413) 
Opioid Number of prescriptions Cost, £ 
Average cost per 
prescription, £ 
Buprenorphine 391 14,204 36 
Codeine/dihydrocodeine 1,551 6,899 4 
Fentanyl 41 2,024 49 
Morphine 288 3,658 13 
Oxycodone 183 11,484 63 
Tapentadol 9 356 40 
Tramadol 856 5,864 7 
TOTAL 3,319 44,491 30 
 
Figure 1 shows the proportions of prescribed opioids. Oral opioids comprised 87%, 
transdermal 13%, and parenteral 0.12% of all opioids prescribed. The most 
frequently prescribed opioid was codeine (47%) which also included combination 
formulations co-codamol (codeine phosphate/paracetamol) and co-dydramol 
(dihydrocodeine/paracetamol). Tramadol was the most frequently prescribed strong 
opioid (26%) followed by buprenorphine (12%), morphine (9%) and oxycodone (6%). 
Parenteral morphine was prescribed to one patient only, although we do know 
whether this was for chronic pain or for acute pain management. Figure 2 illustrates 
the co-prescribing of different opioids in the cohort of patients with chronic 
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musculoskeletal pain. A combination of opioids was prescribed to 32% (132/413) of 
patients. Among these 112 (27%) people received two different types of opioids, 17 
(4%) three different opioids and 3 people (1%) were prescribed more than three 
different opioids. The most frequent combination of opioids was codeine plus 
tramadol (83 people) followed by codeine plus morphine (19 people), codeine plus 
buprenophine (19 people) and morphine plus tramadol (15 people). 
Table 2 summarises numbers of people prescribed different opioids in the entire 
cohort and in the two samples (London and the Midlands). The proportion of people 
with musculoskeletal pain prescribed opioids was higher in the Midlands sample 
(63%) compared to the London sample (56%). Morphine was more frequently 
prescribed in the Midlands (10%) compared to London (3.7%). The average number 
of opioid prescriptions per patient was also higher in the Midlands sample 8.58 (SD 
8.12) compared to the London sample 7.33 (SD 7.56), although this difference was 
not statistically significant. The proportions of patients receiving different 
combinations of opioids were similar in the London and the Midland samples. 
MANOVA tests conducted using prescription numbers for different opioids showed 
no significant differences between London and Midlands samples (P>0.05, not 
shown). 
 
Table 2. Characteristics of opioid prescriptions in the London and Midlands samples. 
Prescription 
characteristics 
London (N=320) Midlands (N=383) Full sample (N=703) 
N % N % N % 
Prescribed opioids 180 56 233 61 413 59 
     Buprenorphine 21 6.6 24 6.3 45 6.4 
     Codeine 130 40.6 150 39.2 280 39.8 
     Fentanyl 5 1.6 3 0.8 8 1.1 
     Morphine 9 2.8 35 9.1 44 6.3 
     Oxycodone 6 1.9 9 2.3 15 2.1 
     Tapentadol 0 0.0 1 0.3 1 0.1 
     Tramadol 71 22.2 96 25.1 167 23.8 
Single opioid 126 39.4 163 42.6 289 41.1 
Combination of opioids 54 16.9 70 18.3 124 17.6 
     2 opioids 48 15.0 57 14.9 105 14.9 
     3 opioids 6 3.3 11 4.6 16 2.3 
     4 opioids 0 0 2 0.8 2 0.5 
     5 opioids 1 0.6 0 0 1 0.2 
Average number of 
opioid prescriptions 
over 12 months 
7.3 (SD 7.6) 8.6 (SD 8.1) 8.0 (SD=7.9) 
 
Table 3 summarises prescription characteristics for people receiving weak and 
strong opioids. More than half of these patients (56%, 231/413) were prescribed 
strong opioids. Patients taking strong opioids received on average 10 prescriptions 
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per year with an annual cost of £174 per patient. Among these people 40% received 
>3 strong opioid prescriptions per year, costing on average £236 per person. 
Patients taking weak opioids received on average five prescriptions a year with an 
annual cost of £24 per person. Within this group 21% of people received >3 
prescriptions per year costing on average £40 per person. 
 
Table 3. Characteristics of opioid prescriptions in patients receiving strong and weak 
opioids (N=413) 
Prescription characteristics 
People 
receiving 
strong opioids 
N=231 
People 
receiving weak 
opioids 
N = 182 
Number of patient prescribed opioids 231 (56%) 182 (44%) 
Annual number of prescriptions 2,332 987 
Annual cost per patient £174  £24 
Average number of prescriptions a year (SD) 10 (9) 5 (5) 
Number of patients receiving >3 prescriptions a year 166 (40%) 88 (21%) 
Average cost per patient receiving >3 prescriptions a 
year £236 £40 
 
Discussion 
In this study we characterised opioid prescribing in a sample of people with chronic 
musculoskeletal pain recruited from primary care into a trial of a self-management 
intervention. Opioids were prescribed to 59% of study participants and 53% of these 
prescriptions were for strong opioids, indicating their frequent prescription for 
patients with chronic musculoskeletal pain. These strong opioids included: tramadol 
(26%), buprenorphine (12%), morphine (9%) and oxycodone (6%). Approximately 
40% of patients received >3 strong opioid prescriptions per year, suggesting long-
term prescribing of strong opioids in primary care. According to the national 
guidelines on chronic pain management for people with low back pain and 
osteoarthritis,15 16 strong opioids are to be only prescribed in unremitting cases for 
short term use, stepping down to weaker opioids, or removing altogether if not 
effective.15 
Currently, there is no accepted definition of over-prescribing. The use of this term 
largely depends on context; it can refer to unnecessary prescription, lack of clinical 
effectiveness, or side effects.35-37 In opioid studies over-prescription is closely 
associated with opioid misuse and abuse.9 23 38 39 Dunn et al.9 analysed the 
relationship between prescribed opioid doses and the risk of overdose in 9,940 
patients with chronic non-malignant pain. People receiving daily morphine equivalent 
doses in the range 50-99 mg have a 3.7-fold increase in overdose risk, while patients 
receiving doses 100 mg or more had an 8.9-fold increase in overdose risk compared 
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to patients prescribed <20 mg/day.9 Given that opioids differ in their potency, 
formulation and administration routes, converting opioid doses to oral morphine 
would be one way of identifying the over-prescription of opioids. However, there are 
differences in the conversion ratios to oral morphine used in the national guidelines 
and formularies.32-34 There is also individual variation in patient response to opioids 
in terms of metabolism, distribution and receptor dynamics.40 41 Therefore, opioid 
conversion ratios are purely guidelines that provide starting points for switching 
between different opioids for the majority of individuals, subject to further 
assessment and dose titration. 
In the context of this study, over-prescribing can be defined as the long-term 
prescribing of strong opioids (>3 prescriptions a year). This is consistent with NICE 
guidelines on chronic pain management, which recommend strong opioids to be 
prescribed for a short time only.15 16 We found that 40% of patients receiving opioids 
for chronic musculoskeletal pain may be over-prescribed. The estimated cost of 
over-prescription was £236 per person per year (Table 3). According to recent 
analyses of opioid prescribing the UK primary care, 1.25 to 1.38 million people with 
musculoskeletal conditions receive long-term opioids.42 Assuming that 40% of these 
people are over-prescribed, the cost of opioid over-prescription may be over a 
hundred million pounds a year. This does not include costs associated with the 
management of side effects and overdose. We were unable to calculate these costs 
since there were no opioid-related adverse events in our study.29  
Although our understanding of chronic pain management has advanced, the 
effective treatment of chronic pain remains elusive. In the chronic pain management 
guidelines for Australia, Canada, Germany, USA and UK, weak opioids are 
considered a treatment option.15 16 43-45 Opioids are used to treat both acute and 
chronic pain, despite pain experts being in agreement over their poor effectiveness 
for the latter.46-48 Some report suggest that prescribing opioids for chronic pain may 
be associated with poorer functional outcomes compared to other treatment 
strategies.49 50 Since the late 1990s, under growing public pressure and aggressive 
pharmaceutical marketing to eliminate pain, physicians globally have been ever 
more proactive in their efforts to identify and treat chronic pain. In the UK, the latest 
published data show that from 2005 to 2015 use of analgesics  rose by 21 million 
items, increasing costs by £230.1 million.51 Among opioids, the increase was 10% for 
oxycodone, 9% for morphine and 9% for buprenorphine.51 Nevertheless, pain 
intensity does not improve in chronic pain patients on higher opioid doses compared 
to lower, indicating poor efficiency in current opioid prescription practice.7-9 Scientific 
literature is flooded with information on the dangers of opioid misuse, abuse and 
addiction as a recreational drug.52-54 However, fatalities from recreational opioid 
misuse are now overshadowed by medically-prescribed opioid related deaths; in the 
USA these accounts for 60% of opioid-related deaths55 and data from the National 
Center for Health Statistics show that opioid deaths have increased above that of the 
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deaths from heroin and cocaine combined.56 Physicians have raised the alarm about 
the rise in opioid prescribing in primary care, saying that in many cases doses are 
too high and treatments are too long 17-19 57 Current guidelines for the management 
of conditions associated with chronic pain14-16 reiterate importance of maintaining 
physical activity, physiotherapy and education programmes. In recent decades, a 
more holistic approach to chronic pain management has been taken. New 
treatments involve self-management, coping strategies such as distraction or 
relaxation techniques, and lower doses of pain relief medication.58 59 The purpose of 
chronic musculoskeletal pain management is to enable the individual to live with the 
pain, yet limit its impact on their daily functioning, adhering more closely to a 
biopsychosocial model of health60. The cost-effectiveness of these therapies is yet to 
be established. The study of a non-pharmacological intervention for people with 
chronic musculoskeletal pain, which generated data for this manuscript, did not find 
any significant effect on pain severity.28 29 However, the intervention was found to be 
cost-effective due to a reduction in depression and an improvement in health-related 
quality of life28 29. Researchers recognise the importance of assessing multiple 
outcomes in pain management studies and that research in pain management 
should go beyond comparing the clinical effectiveness of different treatments, but 
address questions of "what treatment is effective, for which patients, on what 
outcomes, under what circumstances, and at what cost".61 
 
Limitations 
This study provides a snapshot of opioid prescribing in primary care over a period of 
one year; it did not look at longitudinal changes in prescribing opioids to patients with 
chronic musculoskeletal pain. 
This study focused on the economic aspects of opioid prescribing; it did not attempt 
to relate opioid prescriptions with treatment effectiveness. 
Our analysis assumes that all opioid prescriptions were for chronic pain and not for 
acute pain episodes. 
Conclusions 
Long-term prescribing of opioids for chronic musculoskeletal pain is common in 
primary care. More than a quarter of patients receiving strong opioids may have 
been over-prescribed according to national guidelines. The estimated cost of over-
prescribing opioids in UK primary care may be around one hundred million pounds a 
year. 
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Figure 1. Proportional distribution of opioid prescriptions in the overall cohort of 
patients 
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Figure 2. Network plot showing co-prescribing of opioids for 132 patients. Patients 
are indicated by blue circles with numbers, which are linked to prescribed opioids 
(yellow circles). The size of the circles is proportional to the number of prescribed 
opioids.  
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Appendix 1. Unit costs used for costing opioids prescribed in the study. Costs were taken 
from the Prescription Cost Analysis database (PCA 2013). PCA data cover all prescriptions 
dispensed in the community in England (i.e. by community pharmacists, appliance 
contractors, dispensing doctors, and items personally administered by doctors). PCA costs 
may differ from the BNF and the NHS Drug Tariff list prices since these costs may be 
averaged between different pack sizes. 
Prescription item including strength 
Net 
ingredient 
cost per item 
(£) 
Buprenorphine BuTrans_Transdermal Patch 10mcg/hr 32.15 
Buprenorphine BuTrans_Transdermal Patch 20mcg/hr 60.65 
Buprenorphine BuTrans_Transdermal Patch 5mcg/hr 17.47 
Buprenorphine Transdermal Patches 5205 micrograms/hour 23.61 
Buprenorphine Transtec_T/Derm Patch 35mcg/hr (20mg) 27.29 
Buprenorphine Transtec_T/Derm Patch 5205mcg/hr (30mg) 42.93 
Buprenorphine Transtec_T/Derm Patch 70mcg/hr (40mg) 61.99 
Co-Codamol (Codeine Phos/Paracetamol) Co-Codamol Eff_Tab 30mg/500mg 9.19 
Co-Codamol (Codeine Phos/Paracetamol) Co-Codamol Eff_Tab 8mg/500mg 4.91 
Co-Codamol (Codeine Phos/Paracetamol) Co-Codamol_Cap 30mg/500mg 6.06 
Co-Codamol (Codeine Phos/Paracetamol) Co-Codamol_Cap 8mg/500mg 5.60 
Co-Codamol (Codeine Phos/Paracetamol) Co-Codamol_Tab 15mg/500mg 8.61 
Co-Codamol (Codeine Phos/Paracetamol) Co-Codamol_Tab 30mg/500mg 3.77 
Co-Codamol (Codeine Phos/Paracetamol) Co-Codamol_Tab 8mg/500mg 3.05 
Co-Codamol (Codeine Phos/Paracetamol) Codipar_Cap 15mg/500mg 6.59 
Co-Codamol (Codeine Phos/Paracetamol) Kapake_Cap 30mg/500mg 9.29 
Co-Codamol (Codeine Phos/Paracetamol) Solpadol_Tab Eff 30mg/500mg 11.37 
Co-Codamol (Codeine Phos/Paracetamol) Zapain_Cap 30mg/500mg 4.54 
Co-Codamol (Codeine Phos/Paracetamol) Zapain_Capl 30mg/500mg 3.15 
Codeine Phosphate Codeine Phos_Linct 15mg/5ml 1.84 
Codeine Phosphate Codeine Phos_Liq Spec 10mg/5ml 221.50 
Codeine Phosphate Codeine Phos_Tab 15mg 4.41 
Codeine Phosphate Codeine Phos_Tab 30mg 3.74 
Co-Dydramol (Dihydrocodeine/Paracet) Co-Dydramol_Tab 10mg/500mg 3.18 
Dihydrocodeine Tartrate Dhc Continus_Tab 60mg 5.80 
Dihydrocodeine Tartrate Dihydrocodeine Tart_Tab 30mg 4.21 
Fentanyl Durogesic DTrans_T/Derm Patch 12mcg 24.80 
Fentanyl Durogesic DTrans_T/Derm Patch 25mcg 37.68 
Fentanyl Durogesic DTrans_T/Derm Patch 50mcg 72.39 
Fentanyl Fentalis Reservoir_T/Derm Patch 50mcg/hr 83.04 
Fentanyl Fentanyl_Transdermal Patch 100mcg/hr 130.95 
Fentanyl Fentanyl_Transdermal Patch 12mcg/hr 22.52 
Fentanyl Matrifen_Patch 12mcg/hr 18.34 
Morphine 30mg modified release capsules 12.41 
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Morphine Sulphate Filnarine SR_Tab 10mg 3.79 
Morphine Sulphate Morph Sulph_Inj 20mg/1ml Amp 28.33 
Morphine Sulphate Morph Sulph_Oral Soln 10mg/5ml 4.97 
Morphine Sulphate Morph Sulph_Tab 10mg M/R 6.09 
Morphine Sulphate Morphgesic SR_Tab 10mg 4.55 
Morphine Sulphate Mst Continus_Susp Gran Sach 100mg 155.70 
Morphine Sulphate Mst Continus_Susp Gran Sach 200mg 375.89 
Morphine Sulphate Mst Continus_Susp Gran Sach 60mg 91.29 
Morphine Sulphate Mst Continus_Tab 10mg 6.09 
Morphine Sulphate Mst Continus_Tab 15mg 8.40 
Morphine Sulphate Mst Continus_Tab 30mg 11.89 
Morphine Sulphate Mst Continus_Tab 5mg 2.88 
Morphine Sulphate MXL_Cap 150mg 43.35 
Morphine Sulphate MXL_Cap 30mg 12.99 
Morphine Sulphate MXL_Cap 60mg 15.49 
Morphine Sulphate oral solution 20mg/5ml 18.59 
Morphine Sulphate Oramorph_Oral Soln 10mg/5ml 5.00 
Morphine Sulphate Sevredol_Tab 10mg 6.62 
Morphine Sulphate Sevredol_Tab 20mg 15.19 
Morphine Sulphate Zomorph_Cap 10mg 4.07 
Morphine Sulphate Zomorph_Cap 30mg 7.65 
Oxycodone HCl/Naloxone HCl Targinact_Tab 10mg/5mg M/R 35.42 
Oxycodone HCl/Naloxone HCl Targinact_Tab 20mg/10mg M/R 70.12 
Oxycodone HCl/Naloxone HCl Targinact_Tab 5mg/205mg M/R 29.18 
Oxycodone Hydrochloride Carexil_Tab 10mg M/R 31.75 
Oxycodone Hydrochloride Carexil_Tab 5mg M/R 37.00 
Oxycodone Hydrochloride OxyContin_Tab 10mg M/R 25.21 
Oxycodone Hydrochloride OxyContin_Tab 15mg M/R 30.36 
Oxycodone Hydrochloride OxyContin_Tab 20mg M/R 50.58 
Oxycodone Hydrochloride OxyContin_Tab 30mg M/R 63.85 
Oxycodone Hydrochloride OxyContin_Tab 40mg M/R 96.54 
Oxycodone Hydrochloride OxyContin_Tab 5mg M/R 21.59 
Oxycodone Hydrochloride OxyContin_Tab 60mg M/R 130.13 
Oxycodone Hydrochloride OxyContin_Tab 80mg M/R 219.73 
Oxycodone Hydrochloride OxyNorm_Cap 10mg 30.03 
Oxycodone Hydrochloride OxyNorm_Cap 5mg 14.12 
Oxycodone Hydrochloride OxyNorm_Oral Soln 5mg/5ml S/F 14.43 
Tapentadol Hydrochloride Palexia_SR Tab 100mg 48.93 
Tapentadol Hydrochloride Palexia_Tab 50mg 27.76 
Tramadol Hydrochloride Aceon_Tab 200mg M/R 43.25 
Tramadol Hydrochloride Marol_Tab 100mg M/R 8.44 
Tramadol Hydrochloride Marol_Tab 150mg M/R 10.53 
Tramadol Hydrochloride Marol_Tab 200mg M/R 14.24 
Tramadol Hydrochloride Maxitram SR_Cap 100mg 14.41 
Tramadol Hydrochloride Maxitram SR_Cap 50mg 5.29 
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Tramadol Hydrochloride Tradorec XL_Tab 200mg 18.98 
Tramadol Hydrochloride Tradorec XL_Tab 300mg 25.45 
Tramadol Hydrochloride Tramacet_Tab 3705mg/325mg 16.27 
Tramadol Hydrochloride Tramacet_Tab Eff 3705mg/325mg 13.02 
Tramadol Hydrochloride Tramadol HCl_Cap 100mg M/R 21.68 
Tramadol Hydrochloride Tramadol HCl_Cap 150mg M/R 21.89 
Tramadol Hydrochloride Tramadol HCl_Cap 200mg M/R 28.67 
Tramadol Hydrochloride Tramadol HCl_Cap 50mg 3.24 
Tramadol Hydrochloride Tramadol HCl_Cap 50mg M/R 8.80 
Tramadol Hydrochloride Tramadol HCl_Tab 100mg M/R &gn 20.19 
Tramadol Hydrochloride Tramquel SR_Cap 150mg 20.60 
Tramadol Hydrochloride Tramquel SR_Cap 50mg 8.68 
Tramadol Hydrochloride Zydol_Tab Solb 50mg 13.30 
 
 
 
 
 
